7
Participants
Start Date
April 30, 2003
Study Completion Date
May 31, 2004
Voriconazole
Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
Pfizer Investigational Site, Taipei
Pfizer Investigational Site, Taipei
Pfizer Investigational Site, Taichung
Pfizer Investigational Site, Kaohsiung City
Lead Sponsor
Pfizer
INDUSTRY